Recent recruitments of patients at I-Motion

In Italpharmaco trial (Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With DMD), first three patients have been screened last days (January 15th, 22nd and 26th, 2018), that is they are included in the selection part of the study. Thereafter, if these patients are eligible, they will be randomized to placebo or treatment.

Firefish and Sunfish trials seek respectively to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in patients with spinal muscular atrophy type 1 (Firefish) and spinal muscular atrophy type 2 and 3(Sunfish). At this time, 4 patients are randomized in Firefish (part 1), and 2 additional patients will be enrolled in February. Part 2 is planned to start in February in every centers involved. For Sunfish trial, 9 patients are randomized (4 in part 1 and 5 in part 2). In these two studies, enrollments are ongoing.